Cargando…

Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae

OBJECTIVES: To determine the presenting features of ocular surface disease in patients with atopic dermatitis (AD) treated with dupilumab at a tertiary, university hospital. To establish the need for treatment of dupilumab-associated ocular surface disease and report any long-term effects on the ocu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Popiela, Magdalena Z., Barbara, Ramez, Turnbull, Andrew M. J., Corden, Emma, Martinez-Falero, Beatriz Suarez, O’Driscoll, Daniel, Ardern-Jones, Michael R., Hossain, Parwez N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602420/ https://www.ncbi.nlm.nih.gov/pubmed/33504973 http://dx.doi.org/10.1038/s41433-020-01379-9

Ejemplares similares

Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis
por: Maudinet, Adrien, et al.
Publicado: (2019)

Nonsteroid management of residual ocular surface disease on dupilumab (ROSDD),()()
por: Raffi, Jodie, et al.
Publicado: (2019)

Dupilumab-associated cicatrizing ocular disease
por: Reddy, Amit K., et al.
Publicado: (2022)

Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase
por: Park, Sunny, et al.
Publicado: (2021)

Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)(,,)()
por: Raffi, Jodie, et al.
Publicado: (2019)

Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
por: ACHTEN, Roselie E., et al.
Publicado: (2022)

Dupilumab‐associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting
por: Foley, Peter, et al.
Publicado: (2022)

Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series
por: Hébert, Mélanie, et al.
Publicado: (2022)

Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report
por: Zirwas, Matthew J., et al.
Publicado: (2018)

Encounters and medication use for ocular surface disorders among patients treated with dupilumab: A cohort study
por: Barbieri, John S., et al.
Publicado: (2021)

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
por: Achten, Roselie, et al.
Publicado: (2023)

Personal Experiences of the Ocular Sequelæ of Malaria
por: Manson, Wm. Hislop
Publicado: (1920)

Ocular manifestations of emerging viral diseases
por: Venkatesh, Ashwin, et al.
Publicado: (2021)

Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab–Associated Conjunctivitis in Patients with Atopic Dermatitis
por: Patra, VijayKumar, et al.
Publicado: (2023)

Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients
por: Tauqeer, Zujaja, et al.
Publicado: (2022)

Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report
por: Adachi, Rumi, et al.
Publicado: (2022)

Ocular Sequelae of Congenital Toxoplasmosis in Brazil Compared with Europe
por: Gilbert, Ruth E., et al.
Publicado: (2008)

Ocular Adverse Effects in Atopic Dermatitis Patients Treated With Dupilumab: A Bibliometric Analysis
por: Jia, Qian-Nan, et al.
Publicado: (2022)

Novel Use Of Dupilumab In A Patient With Post-Acute Sequelae of SARS-CoV-2 Infection With Severe Persistent Asthma
por: Ashraf, Anam, et al.
Publicado: (2022)

Severe ocular sequelae of congenital toxoplasmosis: huge macular scar
por: Zahir, Fadoua, et al.
Publicado: (2015)

Observations upon Otorrhea as a Sequela to Scarlet Fever
por: Turnbull, Laurence
Publicado: (1858)

Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK
por: O’Kane, D, et al.
Publicado: (2021)

Ocular sequelae in severe COVID-19 recovered patients of second wave
por: Dipu, Taw, et al.
Publicado: (2022)

Ocular Sporotrichosis with Limbal Stem Cell Deficiency: An Impostor with Blinding Sequelae
por: Mohamad, Shahidatul-Adha, et al.
Publicado: (2023)

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
por: Mickevicius, Tomas, et al.
Publicado: (2023)

Giving presentations
por: Ellis, Mark, et al.
Publicado: (1997)

Dupilumab-associated blepharoconjunctivitis
por: Paulose, Sefy A., et al.
Publicado: (2019)

Dupilumab for atopic dermatitis
Publicado: (2019)

Ophiasis treated with dupilumab
por: Abercrombie, McKenna, et al.
Publicado: (2021)

Dupilumab-Induced Pancreatitis
por: Jasti, Vivek V., et al.
Publicado: (2023)

Conjunctivitis in dupilumab clinical trials
por: Akinlade, B., et al.
Publicado: (2019)

Chronic ocular sequelae in Stevens–Johnson syndrome: a genetic association study
por: Sangwan, Sushil K., et al.
Publicado: (2022)

Erythrodermic presentation of psoriasis in a patient treated with dupilumab
por: Tracey, Elisabeth H., et al.
Publicado: (2018)

An Uncharacteristic Presentation of Evans Syndrome Following Treatment With Dupilumab
por: Rutherford, Megan, et al.
Publicado: (2021)

Dupilumab for the treatment of severe photodermatitis
por: Smith, Mary Patricia, et al.
Publicado: (2019)

Successful treatment of trichothiodystrophy with dupilumab
por: Gruber, R., et al.
Publicado: (2021)

The Role of Dupilumab in Severe Asthma
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

Dupilumab-induced erythema nodosum
por: Mustin, Danielle E., et al.
Publicado: (2021)

Dupilumab-induced pityriasis rosea
por: Zabel, Morgan, et al.
Publicado: (2023)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gvk3iati1v2lnteds6b2pqmtn2